Tranexamic acid


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Short-term management of haemorrhage Localised haemorrhage: 1-1.5 g bid or tid. Menorrhagia 1 g tid during menstruation as necessary for up to 5 days. Max: 4 g/day. Hereditary angioedema 1-1.5 g bid or tid intermittently or continuously. Patients with haemophilia undergoing dental extraction 1.5 g 8 hourly. IV Short-term management of haemorrhage Local: 0.5-1 g bid or tid. General: 1 g 6-8 hourly.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Active thromboembolic disease (e.g. pulmonary embolism, DVT), history of venous or arterial thrombosis (including retinal vein or artery occlusion), disseminated intravascular coagulation, fibrinolytic conditions after consumption coagulopathy, history of convulsions. Concomitant use with hormonal contraceptives. Severe renal impairment.
Special Precautions
Patients with enormous haematuria from upper urinary tract, history of thromboembolic diseases. Women with subarachnoid haemorrhage or irregular menstrual cycle. Mild to moderate renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Perform eye examinations at baseline then regularly during treatment.
Adverse Reactions
Significant: Visual and ocular disturbance (e.g. impaired colour vision), retinal vein or artery occlusion, ligneous conjunctivitis, thromboembolic events, convulsions. Blood and lymphatic system disorders: Anaemia. Gastrointestinal disorders: Diarrhoea, nausea, vomiting, abdominal pain. General disorders and administration site conditions: Fatigue. Musculoskeletal and connective tissue disorders: Musculoskeletal pain, muscle cramps. Nervous system disorders: Headache, migraine. Respiratory, thoracic and mediastinal disorders: Nasal and sinus symptoms.
Potentially Fatal: Severe hypersensitivity reactions including anaphylaxis.
Drug Interactions
Antagonistic effects with thrombolytics (e.g. alteplase, reteplase). Increased risk of thrombosis with factor IX complex concentrates or anti-inhibitor coagulant concentrates. May enhance the procoagulant effect of all-trans retinoic acid (oral tretinoin) in women with acute promyelocytic leukaemia.
CIMS Class
ATC Classification
B02AA02 - tranexamic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.
Disclaimer: This information is independently developed by CIMS based on tranexamic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in